2021
DOI: 10.3390/ph14030280
|View full text |Cite
|
Sign up to set email alerts
|

Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a five-year survival rate of around 5%. Treatment of PDAC is still a major challenge, with cytotoxic chemotherapy remaining the basis of systemic therapy. However, no major advances have been made recently, and therap… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 155 publications
(226 reference statements)
0
6
0
Order By: Relevance
“…Recent studies have highlighted the promising potential of repurposing non-oncology drugs for future cancer therapy. Examples include anticoagulant agents (warfarin ( Rebelo et al, 2021 ) and dalteparin ( Agnelli et al, 2022 )), anti-fungi (itraconazole ( Shen et al, 2021 )), antidiabetic drugs (metformin ( Cunha Júnior et al, 2021 ) and linagliptin ( Li Y. et al, 2020 )), antiparasitic (ivermectin ( Nambara et al, 2017 )), anthelminthic (parbendazole ( Son et al, 2020 )), antibiotics (nitroxoline ( Mitrović and Kos, 2019 ), doxycycline ( Ghasemi and Ghasemi, 2022 ), azithromycin ( Qiao et al, 2018 ) and tigecycline ( ElHefnawi et al, 2022 )).…”
Section: Repurposed Drugs For Gastrointestinal Cancers Treatmentmentioning
confidence: 99%
“…Recent studies have highlighted the promising potential of repurposing non-oncology drugs for future cancer therapy. Examples include anticoagulant agents (warfarin ( Rebelo et al, 2021 ) and dalteparin ( Agnelli et al, 2022 )), anti-fungi (itraconazole ( Shen et al, 2021 )), antidiabetic drugs (metformin ( Cunha Júnior et al, 2021 ) and linagliptin ( Li Y. et al, 2020 )), antiparasitic (ivermectin ( Nambara et al, 2017 )), anthelminthic (parbendazole ( Son et al, 2020 )), antibiotics (nitroxoline ( Mitrović and Kos, 2019 ), doxycycline ( Ghasemi and Ghasemi, 2022 ), azithromycin ( Qiao et al, 2018 ) and tigecycline ( ElHefnawi et al, 2022 )).…”
Section: Repurposed Drugs For Gastrointestinal Cancers Treatmentmentioning
confidence: 99%
“…Monensin inhibits colon cancer cell growth by inducing cell cycle arrest and apoptosis [ 116 ]. Therefore, it has been suggested as a potential candidate for repurposing for cancer treatment [ 115 , 117 ].…”
Section: Golgi Stress-inducing Anticancer Natural Productsmentioning
confidence: 99%
“…Some treatments are under clinical investigation, see Table 3 ( , accessed on September 6, 2022). These treatments include galunisertib plus gemcitabine[ 145 ], Janus kinase 1/2 inhibitor ruxolitinib[ 146 ], adoptive transfer of T cells[ 147 ], gemcitabine and trastuzumab plus erlotinib[ 148 ], erlotinib plus gemcitabine[ 149 ], pegilodecakin plus folinic acid, fluorouracil, and oxaliplatin[ 126 ], liposomal irinotecan plus 5-fluorouracil/leucovorin[ 150 ], bevacizumab[ 151 ], and sunitinib[ 152 ].…”
Section: Clinical Trialsmentioning
confidence: 99%